Le Lézard
Classified in: Science and technology
Subject: PDT

Language I/O Releases Most Accurate Machine Translation Tool on the Market


CHEYENNE, Wyo., Oct. 29, 2020 /PRNewswire/ -- Language I/O's proprietary machine translation optimization technology provides the best machine translation across all languages for companies that are struggling to accurately translate industry jargon, newly invented slang, named entities such as a company's product names, acronyms and other messy User Generated Content (UGC).

"There is no other company on the market that aggregates the best machine translation engines and then layers their own technology on top of them so that the messiest UGC is properly translated every time," said Language I/O CEO Heather Morgan Shoemaker.

When a customer opens a chat with a customer service agent, they're often distracted or typing too quickly. This often leads to chats rife with spelling mistakes, jargon and acronyms. Language I/O's machine translation optimizer takes the best machine translation engines on the market and teaches them to recognize and then correctly translate this messy content.

"One of the coolest things about our machine translation optimizer is that we've built it while maintaining our ardent commitment to protecting customer data," Shoemaker said. "Some vendors in the multilingual customer service space hoard conversational content for the purpose of training neural MT (machine translation) engines. We never have and never will do that."

This commitment reinforces Language I/O's strict adherence to international security standards such as the ISO 27001 and GDPR. We also encrypt all personally identifiable information (PII).

Major national brands in the gaming, finance, travel and ecommerce space look to Language I/O to provide best-in-class translations. Many of our customers see an ROI (return on investment) of more than 500% when opting to use our solutions rather than hiring additional, non-English customer support staff. Contact us for more information about our products.

About Language I/O

The future of translation is conversational and Language I/O's proprietary machine translation optimization technology ensures that every conversation is understood. Our machine translation optimizer can translate difficult to translate user generated content such as jargon, slang, abbreviations and misspellings in 150 languages over chat, email, article and social support channels. Language I/O seamlessly integrates within all major (customer relationship management) systems CRMs and also provides an API. Finally, we let customers decide whether to use professional human linguists, our machine translation optimizer, or a combination of the two.

 

SOURCE Language I/O


These press releases may also interest you

at 18:05
GlycoMimetics' product candidate uproleselan ? when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) ? was shown today in an oral presentation to break chemoresistance by dramatically and significantly reducing tumor...

at 18:00
Quanta X Technology, the parent company of QuantaDose, CEO Katie Webb suggests, "Anyone in Santa's shoes gifting a UVC device to a friend or family member needs to make sure the UV-C device is real, and they also need to understand the potential...

at 17:00
63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ?6 months of follow-up, 83% have ongoing responses...

at 16:30
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab (JNJ-64007957) for the treatment of relapsed or refractory multiple...

at 15:30
Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an interim readout to evaluate the...

at 15:05
bluebird bio, Inc. today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene therapy (beti-cel; formerly LentiGlobintm for ?-thalassemia) in patients with transfusion-dependent...



News published on 29 october 2020 at 10:22 and distributed by: